Clinical Trial Update: A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of ribociclib (CDK4/6 inhibitor) following radiation therapy in high-grade glioma and DIPG was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• High-grade Glioma

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-11-05